No price history available.
Key financial summary
Financials in ILA| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ILAm | 721 | 668 | 685 | 734 | 664 | 652 | N/A | N/A |
| Operating profit | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ILAm | 57 | 36 | -36 | 6 | 8 | 4 | N/A | N/A |
| EPS reported | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in ILA| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in 1984 and based in Tel Aviv-Yafo, Israel, Nissan Medical Industries Ltd, operating through its subsidiary, specializes in the production and distribution of spunlace non-woven textiles. These materials find extensive application across diverse sectors, including reusable and disposable consumer items, medical supplies, automotive manufacturing, infrastructure development, and various hygiene products. The company's market reach encompasses the United States, Canada, Europe, and Israel, with product sales managed through its network of sales agents.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Nissan Medical Industries Ltd (NISA.TA)
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1984 and based in Tel Aviv-Yafo, Israel, Nissan Medical Industries Ltd, operating through its subsidiary, specializes in the production and distribution of spunlace non-woven textiles. These materials find extensive application across diverse sectors, including reusable and disposable consumer items, medical supplies, automotive manufacturing, infrastructure development, and various hygiene products. The company's market reach encompasses the United States, Canada, Europe, and Israel, with product sales managed through its network of sales agents.